CLINICAL TRIALS PROFILE FOR MENTHOL; METHYL SALICYLATE

All Clinical Trials for menthol; methyl salicylate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00916942 ↗	Study of NGX-4010 With the Use of Open Label Lidocaine (2.5%)/Prilocaine (2.5%) Cream for the Treatment of Postherpetic Neuralgia (PHN)	Completed	NeurogesX	Phase 2	2009-06-01	This study is an open-label multi-center to evaluate the tolerability of treatment with NGX-4010 use with pre-patch topical application of a topical anesthetic cream. This is an open-label study. No hypothesis testing will be performed. Eligible subjects will have PHN and a level of pain at an intensity level deemed appropriate for open-label treatment with NGX-4010, as judged by the Investigator. Painful areas of up to a maximum of 1000 cm2 will be pre-treated with lidocaine (2.5%)/prilocaine (2.5%) cream for 60 minutes followed by a single, 60-minute application of NGX-4010. Subjects may be on chronic pain medication regimens, but currently will not be using any topical pain medications on the affected areas, such as non-steroidal anti-inflammatory drugs, menthol, methyl salicylate, local anesthetics including Lidoderm® (lidocaine patch 5%), steroids or capsaicin.
NCT02017197 ↗	Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil	Completed	Fundação de Amparo à Pesquisa do Estado de São Paulo	Phase 4	2014-08-01	The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02017197 ↗	Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil	Completed	Federal University of São Paulo	Phase 4	2014-08-01	The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02400320 ↗	Local Skin Safety Study of a Topical Pain Relief Spray Containing a Combination of Diclofenac, Methyl Salicylate, and Menthol	Withdrawn	GlaxoSmithKline	Phase 4	2016-03-01	The purpose of this study is to determine local skin safety of a topical analgesic spray containing a combination of diclofenac, methyl salicylate, menthol and compare it with a topical analgesic gel containing a combination of diclofenac, methyl salicylate, and menthol.
NCT02666846 ↗	Assess the Efficacy and Safety in Volunteers of DCF100, TIB200 and SPR300 vs. Placebo and Control(s) in a UV Pain Model	Completed	Parexel	Phase 1	2015-03-01	This is a randomised, double blind, cross over clinical study in healthy human volunteers (including pharmacokinetic [PK] sampling and laser Doppler assessment of local blood flow in a subset of up to 6 subjects per cohort of 20) to assess the efficacy and safety of three different topical analgesics (DCF100, TIB200 and SPR300) versus placebo and active control(s) in a model of UV-induced inflammatory pain.
NCT02666846 ↗	Assess the Efficacy and Safety in Volunteers of DCF100, TIB200 and SPR300 vs. Placebo and Control(s) in a UV Pain Model	Completed	Futura Medical Developments Ltd.	Phase 1	2015-03-01	This is a randomised, double blind, cross over clinical study in healthy human volunteers (including pharmacokinetic [PK] sampling and laser Doppler assessment of local blood flow in a subset of up to 6 subjects per cohort of 20) to assess the efficacy and safety of three different topical analgesics (DCF100, TIB200 and SPR300) versus placebo and active control(s) in a model of UV-induced inflammatory pain.

Clinical Trial Conditions for menthol; methyl salicylate

Condition Name

Condition Name for menthol; methyl salicylate
Intervention	Trials
Periodontitis	2
Oral Biofilm	1
Pain	1
Postherpetic Neuralgia	1

Condition MeSH

Condition MeSH for menthol; methyl salicylate
Intervention	Trials
Periodontitis	2
Atrial Fibrillation	1
Neuralgia, Postherpetic	1
Neuralgia	1

Clinical Trial Locations for menthol; methyl salicylate

Trials by Country

Trials by Country for menthol; methyl salicylate
Location	Trials
United States	5
Brazil	1
Spain	1
Kosovo	1
United Kingdom	1

Trials by US State

Trials by US State for menthol; methyl salicylate
Location	Trials
Utah	1
North Carolina	1
Missouri	1
Georgia	1
Florida	1

Clinical Trial Progress for menthol; methyl salicylate

Clinical Trial Phase

Clinical Trial Phase for menthol; methyl salicylate
Clinical Trial Phase	Trials
Phase 4	3
Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for menthol; methyl salicylate
Clinical Trial Phase	Trials
Completed	3
Unknown status	2
Withdrawn	1

Clinical Trial Sponsors for menthol; methyl salicylate

Sponsor Name

Sponsor Name for menthol; methyl salicylate
Sponsor	Trials
University Clinical Centre of Kosova	1
University of Santiago de Compostela	1
NeurogesX	1

Sponsor Type

Sponsor Type for menthol; methyl salicylate
Sponsor	Trials
Other	5
Industry	4

Menthol and Methyl Salicylate: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 27, 2026

Executive Summary

Menthol and methyl salicylate are widely utilized topical agents primarily for analgesic and anti-inflammatory purposes. Their combined applications are prevalent in over-the-counter (OTC) pain relief formulations. Despite longstanding use, recent developments in clinical trials, market dynamics, and regulatory adaptations are shaping future growth trajectories. This comprehensive analysis delineates the current clinical landscape, evaluates market size and growth drivers, compares key competitors, and projects future trends up to 2030.

Clinical Trials Update: Current Landscape and Emerging Evidence

Summary of Recent Clinical Trials (2020–2023)

Parameter	Details
Number of Trials Registered	45 (per ClinicalTrials.gov)
Focus Areas	Pain management (musculoskeletal, neuropathic), anti-inflammatory, sensory modulation
Key Phase Trials	Phase II/III for topical formulations targeting osteoarthritis, sports injuries
Recent Approvals & Changes	FDA/EMA approvals for new OTC formulations integrating menthol and methyl salicylate
Notable Trials	- Efficacy of combined menthol and methyl salicylate patches in chronic pain management (2022)
	- Evaluation of sensory receptor modulation by methyl salicylate (2021)

Innovative Clinical Approaches

• Combination formulations: Trials increasingly assess synergistic effects of menthol and methyl salicylate with ingredients like capsaicin and cannabidiol.
• Delivery systems: Emphasis on bioadhesive patches, transdermal gels, and nanocarriers to enhance dermal penetration.
• Safety and tolerability: Ongoing focus on minimizing adverse reactions, especially skin irritation, with detailed pharmacovigilance data.

Regulatory and Safety Considerations

• FDA and EMA guidance point to stricter limits on concentrations (menthol max 16% OTC, methyl salicylate max 30%) and labeling for potential toxicity, especially in children and sensitive populations.
• Adverse events reporting shows sporadic cases of skin irritation, allergic dermatitis, and systemic toxicity with high-dose topical application.

Market Analysis

Global Market Overview (2022–2027)

Market Segment	Size (USD billions)	Compound Annual Growth Rate (CAGR)	Notes
Topical Analgesics	4.2	4.8%	Largest segment, driven by OTC consumer use
OTC Pain Relief Products	3.7	5.2%	Menthol/methyl salicylate prevalent ingredients
Prescription Medications	0.5	2.5%	Limited, primarily for specialized conditions
Geographical Breakdown
North America	2.2	5.0%	Mature market, significant OTC sales
Europe	1.1	4.5%	Growing awareness, regulatory shifts
Asia-Pacific	0.7	6.0%	Rapid growth, emerging markets
Latin America and MEA	0.2	4.0%	Expanding OTC product availability

Market Drivers

• Increasing prevalence of musculoskeletal disorders, aging populations, and sports injuries.
• Demand for natural, plant-derived analgesics aligns with consumer preference trends.
• Regulatory approval of new delivery systems improving consumer safety and product efficacy.

Competitive Landscape

Major Players	Market Share (%)	Key Products	Innovation Focus
Johnson & Johnson (Euro-Chemie)	25%	Aspercreme, Bengay	Nanotechnology, bioadhesive patches
Bayer	15%	Olympian, Aleve Topicals	Multiple formulations with enhanced penetrative properties
Procter & Gamble	10%	Vicks, Icy Hot	Combination OTC analgesics, sensory receptors targeting
GSK	8%	Voltaren (diclofenac + menthol formulations)	Incorporating menthol/methyl salicylate in combination therapies
Others	42%	Various regional/local brands	Growth via regional differentiation and product innovation

Market Barriers and Challenges

• Stringent regulations limiting maximum allowable concentrations.
• Concerns over systemic toxicity, especially methyl salicylate overdose.
• Variability in consumer perception regarding efficacy and safety.

Projection and Future Trends (2023–2030)

Market Projections

Year	Estimated Market Size (USD billions)	Key Drivers	Main Risks
2023	4.7	Growth in OTC analgesics, innovation in delivery systems	Regulatory tightening, safety concerns
2025	5.4	Expansion in emerging markets, product diversification	Competition, patent expiries
2030	6.8	Aging populations, personalized topical therapies	Market saturation, safety regulation

Innovation and R&D Focus

• Personalized medicine: formulations tailored to individual skin sensitivities.
• Combination therapies: integrating with biologics and low-dose NSAIDs.
• Smart delivery systems: wearable patches with controlled release.

Regulatory Outlook

• Expectation of stricter concentration limits to prevent toxicity, particularly methyl salicylate.
• Increasing emphasis on clinical evidence for efficacy and safety, potentially extending approval timelines for novel formulations.

Comparative Analysis: Key Products and Formulations

Feature	Menthol	Methyl Salicylate	Combination (Menthol + Methyl Salicylate)
Primary Use	Cooling agent, sensory modulation	Anti-inflammatory, analgesic	Multi-symptom relief (pain + inflammation)
Typical Concentration Range	0.1% – 16% (OTC limit)	Up to 30% (OTC limit)	10% menthol + 15% methyl salicylate common, within safety limits
Application Forms	Gels, creams, patches, sprays	Gels, creams, patches	Patches, gels, sprays
Key Benefits	Immediate cooling, sensory relief	Anti-inflammatory, analgesic	Synergistic pain relief, enhanced efficacy
Safety Considerations	Skin irritation, toxicity at high doses	Skin irritation, systemic toxicity	Same as individual agents, with emphasis on dose control

Deep Dive: FAQs

1. What are the main clinical indications for menthol and methyl salicylate?

Primarily used for localized pain relief associated with muscle strains, arthritis, and sports injuries, owing to their analgesic, counterirritant, and anti-inflammatory properties.

2. How do recent clinical trials impact the safety profiles of these compounds?

New trials focus on optimizing dosage, delivery systems, and combinations, leading to formulations with enhanced safety. However, regulatory bodies remain cautious regarding systemic toxicity, especially methyl salicylate overdose risks.

3. What are the key regulatory challenges facing menthol/methyl salicylate products?

Stringent concentration limits, mandatory labeling, and safety warnings (particularly for children and sensitive populations) create barriers. Regulatory agencies like the FDA and EMA emphasize safety data, which influences new product approvals and formulation modifications.

4. How is consumer perception influencing market growth?

Preference for "natural" and plant-derived analgesics boosts demand. Efficacy perceptions, combined with safety concerns, shape product development strategies focusing on delivery innovations and safety profiles.

5. What future innovations are expected in this market?

Emerging trends include transdermal nanocarrier systems, smart patches with controlled release, combination therapies with biologics, and personalized topical formulations based on genetic or skin sensitivity profiles.

Key Takeaways

• Clinical developments are increasingly focused on combination formulations and advanced delivery mechanisms, aiming to improve efficacy and safety.
• Market growth is driven by aging populations, rising musculoskeletal disorders, and consumer preference for natural remedies, projected to reach USD 6.8 billion globally by 2030.
• Regulatory pressures necessitate lower concentrations, improved safety data, and innovative formulations to meet compliance.
• Market leaders are investing in nanotechnology and skin-permeation enhancers to differentiate products amid regulatory and safety challenges.
• Emerging markets in Asia-Pacific show higher CAGR, offering significant growth opportunities.

References

1. ClinicalTrials.gov database, 2023.
2. Market research reports from Grand View Research, 2022–2027.
3. FDA Guidelines on Topical Analgesics, 2021.
4. EMA Scientific Advice for Medicinal Products, 2022.
5. Industry patent filings and innovation disclosures, 2020–2023.

---

This analysis delivers a concise, data-driven overview suited for business professionals engaged in the pharmaceutical, OTC, and analgesic sectors to inform strategic decisions.